Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 6:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 9,581 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: standard of care treatment Clear all
Enrolling by invitation Phase 1Phase 2 Interventional

Evaluation of Lymphatic Response to Physiotherapy in Patients With Swelling Associated With Superficial Venous Disease

NCT07165340
View directory record Official record
Conditions
Chronic Venous Disease
Interventions
Indocyanine Green near infrared fluorescence imaging, advanced pneumatic compression, Duplex ultrasound, compression wrap
Combination Product · Device · Diagnostic Test
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 13, 2026, 6:08 PM EDT
Recruiting Phase 1 Interventional

Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation

NCT07025538
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm
Interventions
Best Practice, Biomarker Analysis, Biospecimen Collection, Questionnaire Administration, Ruxolitinib
Other · Procedure · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 13, 2026, 6:08 PM EDT
Active, not recruiting Phase 3 Interventional

Pentoxifylline and Tocopherol (PENTO) in the Treatment of Medication-related Osteonecrosis of the Jaw (MRONJ)

NCT03040778
View directory record Official record
Conditions
Medication-related Osteonecrosis of the Jaw, Bisphosphonate-related Osteonecrosis of the Jaw, Avascular Necrosis
Interventions
Pentoxifylline, Placebo, Tocopherol
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
4
States / cities
Birmingham, Alabama • Ann Arbor, Michigan • Lake Success, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 13, 2026, 6:08 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

The PRIME Study: A Randomized, Controlled, Prospective Study

NCT04549935
View directory record Official record
Conditions
Patient Preference, Patient Outcomes, Post-Operative Inflammation, Grade of Post-Operative Cystoid Macular Edema, Rate of Post-Operative Cystoid Macular Edema
Interventions
Dextenza, Topical Prednisolone
Drug
Lead sponsor
Vance Thompson Vision - MT
Other
Eligibility
22 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 13, 2026, 6:08 PM EDT
Completed Phase 3 Interventional Results available

Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF

NCT02101268
View directory record Official record
Conditions
Primary Myelofibrosis (PMF), Post-polycythemia Vera (Post-PV), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
Interventions
Momelotinib, Best Available Therapy (BAT)
Drug
Lead sponsor
Sierra Oncology LLC - a GSK company
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
13
States / cities
Los Angeles, California • Gainesville, Florida • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Oct 13, 2026, 6:08 PM EDT
Recruiting Phase 2 Interventional

Telehealth Intervention for Ostomy Self-Management

NCT06528990
View directory record Official record
Conditions
Colorectal Cancer, Bladder Cancer
Interventions
Telehealth Intervention, Standard of care
Behavioral · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 13, 2026, 6:08 PM EDT
Completed Phase 2 Interventional Results available

Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations

NCT02130193
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Danirixin, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 70 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Birmingham, Alabama • Denver, Colorado • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 13, 2026, 6:08 PM EDT
Recruiting Not applicable Interventional

Remotely-Delivered Cognitive Behavioral Stress Management for Breast Cancer (R-CBSM)

NCT07502352
View directory record Official record
Conditions
Breast Cancer
Interventions
Remotely Delivered Cognitive Behavioral Stress Management Intervention (R-CBSM), Standard of Care Survivorship Care Planning
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
50 Years and older · Female only
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 13, 2026, 6:08 PM EDT
Completed Phase 2 Interventional

Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome

NCT02462252
View directory record Official record
Conditions
Aplastic Anemia, Hypoplastic Myelodysplastic Syndrome
Interventions
BL-8040, horse anti-thymocyte globulin (hATG), Methylprednisolone, Cyclosporine
Drug
Lead sponsor
BioLineRx, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Oct 13, 2026, 6:08 PM EDT
Completed No phase listed Observational

Peripheral Venous Oxygen Saturation and Biomarkers to Estimate Cardiac Output and Filling Pressures in Heart Failure

NCT00595738
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Standard of care therapy for severe decompensated heart failure
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2011 · Synced Oct 13, 2026, 6:08 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

A Randomized Comparison of AmnioClear™ Human Allograft Amniotic Membrane vs. Moist Wound Dressing in the Treatment of Diabetic Wounds

NCT02120755
View directory record Official record
Conditions
Diabetic Foot Ulcers, Wound Care
Interventions
AmnioClear™ Human Allograft Amniotic Membrane
Biological
Lead sponsor
Liventa Bioscience
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 3, 2016 · Synced Oct 13, 2026, 6:08 PM EDT
Completed Not applicable Interventional

A Reinforcement Approach to Improve Diabetes Management

NCT02167243
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Reinforcement for BG testing, Standard of care
Behavioral · Other
Lead sponsor
Yale University
Other
Eligibility
12 Years to 21 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 13, 2026, 6:08 PM EDT
Recruiting Phase 1Phase 2 Interventional

Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer

NCT03516708
View directory record Official record
Conditions
Rectal Cancer
Interventions
Epacadostat, Short-course radiation therapy, CAPOX chemotherapy, FOLFOX chemotherapy
Drug · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
4
States / cities
Orange, California • Boston, Massachusetts • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 13, 2026, 6:08 PM EDT
Terminated Phase 2 Interventional Results available

Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary Site

NCT05110781
View directory record Official record
Conditions
Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
Interventions
Atezolizumab, Radiation Therapy, Therapeutic Conventional Surgery
Biological · Radiation · Procedure
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 13, 2026, 6:08 PM EDT
Not listed Phase 4 Interventional

Evaluation of Liposomal Bupivacaine Compared to Usual Care and Its Effects on Pain for Cardiac Surgery

NCT04065919
View directory record Official record
Conditions
Cardiothoracic Surgery
Interventions
Liposomal bupivacaine, 0.25% Bupivacaine with epinephrine
Drug
Lead sponsor
Florida Heart and Lung Institute
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 6, 2020 · Synced Oct 13, 2026, 6:08 PM EDT
Completed No phase listed Observational

Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients

NCT03885830
View directory record Official record
Conditions
CML, Chronic Phase, CML (Chronic Myelogenous Leukemia, CML - Philadelphia Chromosome, Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, Chronic Phase
Interventions
Bosutinib, Dasatinib, Imatinib, Nilotinib
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Oct 13, 2026, 6:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Digital Community to Improve Health in Rural Areas

NCT05363865
View directory record Official record
Conditions
HIV Infections, Hepatitis C Virus Infection
Interventions
Virtual Community Intervention, Standard of Care
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 99 Years
Enrollment
511 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 13, 2026, 6:08 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer

NCT07590934
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
AZD2265 (FPI-2265), Palacaparib (AZD9574), Docetaxel, AZD2287 (Imaging agent)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years · Male only
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
11
States / cities
Duarte, California • Encino, California • South Pasadena, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 13, 2026, 6:08 PM EDT
Completed Phase 1 Interventional Results available

A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma

NCT03283696
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Olaratumab, Doxorubicin, Ifosfamide, Mesna
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Miami, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced Oct 13, 2026, 6:08 PM EDT
Terminated Not applicable Interventional

Health Partner Evaluation at Princeton

NCT03386786
View directory record Official record
Conditions
Total Knee Arthroplasty; Total Hip Arthroplasty
Interventions
Health Partner, Standard Care
Behavioral
Lead sponsor
DePuy Orthopaedics
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Plainsboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Oct 13, 2026, 6:08 PM EDT
Completed Not applicable Interventional

Study to Determine if Using Ventilation During Open Heart Surgery Improves Lung Outcomes

NCT01522222
View directory record Official record
Conditions
Coronary Artery Disease, Heart Failure
Interventions
continuous, mechanical ventilatory support
Procedure
Lead sponsor
Aurora BayCare Medical Center
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Green Bay, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 14, 2018 · Synced Oct 13, 2026, 6:08 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection

NCT04508023
View directory record Official record
Conditions
Coronavirus Disease 2019 (COVID-19)
Interventions
Rivaroxaban, Placebo, Standard of Care (SOC)
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
17
States / cities
Tucson, Arizona • Los Angeles, California • Oakland, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Oct 13, 2026, 6:08 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery

NCT05316688
View directory record Official record
Conditions
Oral Cavity Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8
Interventions
Near Infrared Imaging, Therapeutic Conventional Surgery, Tozuleristide
Procedure · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 13, 2026, 6:08 PM EDT
Completed Phase 3 Interventional Results available

RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag

NCT00370331
View directory record Official record
Conditions
Purpura, Thrombocytopaenic, Idiopathic
Interventions
eltrombopag, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
26
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 13, 2026, 6:08 PM EDT